Identifying and validating predictive and prognostic biomarkers in male Germ Cell Tumours to improve the management and outcomes in both stage 1 and disseminated disease.

Testicular cancer (germ cell tumour) is the most common cancer in young men, and while most cases are curable, doctors don't yet fully understand why some tumours come back after treatment and others don't. This study, run by the Walter and Eliza Hall Institute, aims to build a biobank and data registry to track patients over time and identify markers in the blood and tumour tissue that might predict who is at higher risk of relapse. Participants will continue with their standard cancer treatment while providing blood and tissue samples every six months during active surveillance. Questionnaires will also be completed periodically. This information will help researchers understand the biology of these tumours at a deeper level. You may be eligible if you are male, 18 or older, and have been confirmed to have a germ cell tumour (either a seminoma or non-seminoma type). You must be able to attend follow-up appointments and be willing to provide blood and tissue samples. Men who do not have archival tissue available or who cannot be followed up are not eligible.